Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
— 11 份獲得認可的摘要，包括重申LUMRYZ滿意度、偏好和臨床益處的新數據 —
– Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care –
— 演講強調了Avadel對解決發作性睡病護理差距的持續承諾—
DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.
都柏林，2024年5月22日（GLOBE NEWSWIRE）——專注於改造藥物以改變生活的公司Avadel Pharmicals plc（納斯達克股票代碼：AVDL）今天宣佈，將在2024年6月1日至5日的美國睡眠醫學學會和睡眠研究學會第38屆年度聯席會議SLEEP 2024上展示11張海報和一份口頭演講，支持使用LUMRYZ作爲發作性睡病治療選擇，在休斯頓。
譯文內容由第三人軟體翻譯。